Phase II trial of Avastin [bevacizumab] plus bortezomib for patients with recurrent malignant glioma

Trial Profile

Phase II trial of Avastin [bevacizumab] plus bortezomib for patients with recurrent malignant glioma

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Bortezomib (Primary)
  • Indications Glioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Feb 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
    • 28 May 2013 Planned number of patients changed from 61 to 56 as reproted by ClinicalTrials.gov.
    • 28 May 2013 Planned end date changed from 1 Aug 2012 to 1 Aug 2014 as reproted by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top